Clinical Trial Update: The Role of Tranexamic Acid in Reducing Blood Transfusion Requirements After Cardiopulmonary Bypass in Neonates

View source ↗

Summary

A clinical trial evaluating tranexamic acid to reduce blood transfusion requirements after cardiopulmonary bypass in neonates has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Congenital Heart Disease

Drugs mentioned

• TRANEXAMIC ACID (TRANEXAMIC ACID)

Snippet

Sponsor: Aymen N Naguib | Conditions: Congenital Heart Disease | Status: WITHDRAWN